BlackRock
VRCA icon

BlackRock’s Verrica Pharmaceuticals VRCA Stock Holding History

BlackRock’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Buy
38,553
+32,868
+578% +$210K ﹤0.01% 4763
2025
Q4 		$47.2K Sell
5,685
-463
-8% -$2.57K ﹤0.01% 5068
2025
Q3 		$26.5K Buy
6,148
+501
+9% +$3.02K ﹤0.01% 5100
2025
Q2 		$29.9K Sell
5,647
-117,108
-95% -$630K ﹤0.01% 5080
2025
Q1 		$543K Buy
122,755
+3,799
+3% +$24.6K ﹤0.01% 4375
2024
Q4 		$833K Buy
118,956
+10,412
+10% +$114K ﹤0.01% 4268
2024
Q3 		$1.57M Sell
108,544
-4,370
-4% -$197K ﹤0.01% 4065
2024
Q2 		$8.23M Buy
112,914
+1,508
+1% +$116K ﹤0.01% 3484
2024
Q1 		$6.6M Sell
111,406
-2,168
-2% -$120K ﹤0.01% 3558
2023
Q4 		$8.31M Buy
113,574
+8,469
+8% +$348K ﹤0.01% 3488
2023
Q3 		$4.08M Buy
105,105
+4,767
+5% +$242K ﹤0.01% 3733
2023
Q2 		$5.79M Buy
100,338
+89,671
+841% +$5.44M ﹤0.01% 3666
2023
Q1 		$693K Buy
10,667
+2,181
+26% +$132K ﹤0.01% 4453
2022
Q4 		$233K Sell
8,486
-19,444
-70% -$519K ﹤0.01% 4808
2022
Q3 		$816K Buy
27,930
+6,763
+32% +$232K ﹤0.01% 4553
2022
Q2 		$407K Sell
21,167
-56,815
-73% -$2.86M ﹤0.01% 4839
2022
Q1 		$6.32M Sell
77,982
-1,465
-2% -$121K ﹤0.01% 3830
2021
Q4 		$7.28M Buy
79,447
+14,925
+23% +$1.69M ﹤0.01% 3838
2021
Q3 		$8.07M Sell
64,522
-5,762
-8% -$646K ﹤0.01% 3769
2021
Q2 		$7.94M Buy
70,284
+161
+0.2% +$19.5K ﹤0.01% 3727
2021
Q1 		$10.6M Sell
70,123
-1,766
-2% -$244K ﹤0.01% 3531
2020
Q4 		$8.28M Buy
71,889
+3,411
+5% +$313K ﹤0.01% 3468
2020
Q3 		$5.3M Sell
68,478
-3,332
-5% -$273K ﹤0.01% 3552
2020
Q2 		$7.91M Sell
71,810
-1,105
-2% -$128K ﹤0.01% 3318
2020
Q1 		$7.97M Buy
72,915
+188
+0.3% +$24.7K ﹤0.01% 3114
2019
Q4 		$11.6M Buy
72,727
+3,202
+5% +$472K ﹤0.01% 3170
2019
Q3 		$10.3M Buy
69,525
+6,081
+10% +$678K ﹤0.01% 3198
2019
Q2 		$7.37M Buy
63,444
+15,068
+31% +$1.41M ﹤0.01% 3385
2019
Q1 		$5.23M Buy
48,376
+21,609
+81% +$2.49M ﹤0.01% 3391
2018
Q4 		$2.18M Buy
26,767
+1,254
+5% +$152K ﹤0.01% 3634
2018
Q3 		$4.14M Buy
+25,513
New +$4.36M ﹤0.01% 3555

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock's VRCA Position: Q1 2026 in Review

BlackRock increased its Verrica Pharmaceuticals (VRCA) stake by 578% in Q1 2026, buying an estimated $210K and bringing the position to 38,553 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #4763.

BlackRock first reported a position in VRCA in Q3 2018 and has held it in 31 quarters since. The position peaked at $11.6M in Q4 2019. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • BlackRock held 38,553 shares of Verrica Pharmaceuticals worth $204K as of Q1 2026.
  • BlackRock bought 32,868 Verrica Pharmaceuticals shares in Q1 2026, an estimated $210K.
  • Verrica Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4763 holding.
  • BlackRock first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • BlackRock's Verrica Pharmaceuticals position peaked at $11.6M in Q4 2019.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.